TAK-653 (Osavampator) — Safety, Research, Risks & Legal Status

Not medical advice. TAK-653 (Osavampator) is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Osavampator, NBI-1065845, TAK-653, CAS 1358751-06-0
Category	Research Chemical
Drug class	AMPA receptor positive allosteric modulator (PAM), minimal agonist activity
Developers	Takeda / Millennium (originator); Neurocrine Biosciences (partner)
Trial stage	Phase 3 (adjunctive MDD); Phase 2 SAVITRI positive at 1 mg
Route	Oral, once daily
Investigational indication	Major depressive disorder, adjunct to antidepressants
Half-life	Approximately 33 to 48 hours
US legal status	Not FDA-approved for any indication and not a lawful dietary supplement. As osavampator (NBI-1065845/TAK-653) it is an investigational new drug in Phase 3 trials, meaning it lives in a regulated development pipeline, not the consumer market. Material sold to individuals online comes from gray-market vendors labeled "for laboratory research use only, not for human consumption," which places human use outside the lawful and intended channel. It is not a scheduled controlled substance in the US as of this writing, but the research-chemical framing means no FDA review for OTC use and no manufacturing oversight for consumer products. Informational only; Peptropix does not sell it.

What is TAK-653 (Osavampator)?

TAK-653, development name osavampator (also NBI-1065845), is a selective positive allosteric modulator (PAM) of the AMPA subtype of glutamate receptor. It is being developed as an investigational antidepressant, specifically an adjunctive therapy for major depressive disorder (MDD) in adults with inadequate response to standard oral antidepressants. Unlike direct AMPA agonists, it has minimal intrinsic agonist activity: it amplifies signaling only where glutamate is already present, a design intended to reduce the seizure and excitotoxicity risks that undermined earlier compounds in this class. It is co-developed by Takeda (originator, via Millennium Pharmaceuticals) and Neurocrine Biosciences. Despite appearing on gray-market nootropic sites, it is an unapproved investigational drug, not a supplement or established cognitive enhancer.

How it works

TAK-653 binds an allosteric site on AMPA-type ionotropic glutamate receptors and acts as a positive allosteric modulator: it slows receptor desensitization and internalization, increasing charge transfer when the receptor's orthosteric site is occupied by endogenous glutamate. A defining feature is its near-absence of intrinsic agonist activity, so it potentiates only where glutamatergic signaling already occurs rather than driving the receptor on its own. The proposed antidepressant pathway is that enhanced AMPA throughput increases downstream BDNF release and mTOR signaling, promoting synaptic plasticity, an axis implicated in the rapid antidepressant action of ketamine. This is framed as a way to engage ketamine-like plasticity mechanisms without the NMDA-blockade-driven dissociative or psychotomimetic effects. Much of the downstream signaling account rests on rodent and cell-culture data.

Background & history

TAK-653 originated at Takeda (through Millennium Pharmaceuticals) as part of a program to develop AMPA receptor potentiators after older ampakines (for example CX- and LY-series compounds) struggled with narrow therapeutic windows and weak efficacy. It was designed for glutamate-dependent potentiation with minimal agonism to widen the safety margin. Under a Takeda-Neurocrine collaboration it advanced as NBI-1065845 and was later named osavampator. Phase 2 SAVITRI results (reported 2024) were positive at the 1 mg dose, and a Phase 3 adjunctive-MDD program initiated in 2025. In a January 2025 amendment, Japanese rights returned to Takeda while Neurocrine retained rights for the rest of the world. The gray-market nootropic presence emerged separately once the chemistry was published, independent of the sponsors.

What the research says

Human data are limited but more advanced than for most compounds in this class. Phase 1 healthy-volunteer studies characterized safety, pharmacokinetics, and CNS pharmacodynamics; a transcranial magnetic stimulation study reported increased cortical excitability (motor-evoked potentials) consistent with target engagement, and investigators noted at least some stimulant-like effects, though less pronounced than classic psychostimulants. The pivotal human efficacy signal is the Phase 2 SAVITRI trial (183 adults with MDD and inadequate antidepressant response), where once-daily 1 mg osavampator produced a statistically significant reduction in MADRS depression scores versus placebo (primary endpoint at day 28, P=0.0159; day 56, P=0.0016), while the 3 mg dose did not reach significance. A Phase 3 registrational program began enrolling in 2025. Cognitive-enhancement claims in healthy people are preclinical and mechanistic, not established by robust human trials; the antidepressant data are the strongest human evidence and are still investigational.

Reported effects

Investigated for reduction in depression severity (MADRS) as an add-on to antidepressants in MDD
Increased cortical excitability / target engagement seen on TMS in healthy volunteers
Reported mild stimulant-like effects in early human studies
Preclinical: antidepressant-like behavior in rodent models
Preclinical/theoretical: pro-cognitive and synaptic-plasticity effects via AMPA potentiation
Proposed downstream BDNF and mTOR signaling increases (rodent/cell data)

Dosing & administration (informational)

Informational only, not a protocol and not advice. The only well-characterized human dosing comes from clinical trials: the SAVITRI Phase 2 study used once-daily oral doses of 1 mg and 3 mg, with 1 mg emerging as the efficacious and selected dose for Phase 3, dosed under medical supervision with monitoring. Phase 1 work used single and multiple ascending doses in healthy volunteers. Gray-market vendors sell arbitrary powder and solution concentrations, but no self-administration regimen has been validated for safety or efficacy. Any figures here describe what appears in the literature, not a recommendation to dose.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No robust long-term human safety data outside monitored clinical trials; unknown risks with chronic self-administration
Most common trial adverse events at effective dose were headache and nasopharyngitis, at rates near placebo; no serious adverse events reported at 1 mg or 3 mg in SAVITRI
AMPA potentiation carries a theoretical seizure/excitotoxicity concern; TAK-653 was engineered for a wide preclinical convulsion safety margin, but this does not guarantee safety in unsupervised human use
Stimulant-like effects were noted in early studies; interaction with sleep, anxiety, or seizure-threshold-lowering drugs is not characterized outside trials
Long elimination half-life (roughly 33 to 48 hours) means accumulation with repeated dosing
Gray-market product has no verified identity, purity, or dose; contamination and mislabeling are realistic risks
Not evaluated for use in pregnancy, adolescents, or people with psychiatric or seizure history outside controlled settings

Drug & supplement interactions

F
o
r
m
a
l
d
r
u
g
-
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
a
r
e
l
i
m
i
t
e
d
t
o
s
p
o
n
s
o
r
-
r
u
n
s
t
u
d
i
e
s
.
A
p
u
b
l
i
s
h
e
d
P
h
a
s
e
1
s
t
u
d
y
e
x
a
m
i
n
e
d
N
B
I
-
1
0
6
5
8
4
5
e
f
f
e
c
t
s
o
n
t
h
e
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
s
o
f
m
i
d
a
z
o
l
a
m
(
a
C
Y
P
3
A
p
r
o
b
e
)
a
n
d
a
n
e
t
h
i
n
y
l
e
s
t
r
a
d
i
o
l
-
l
e
v
o
n
o
r
g
e
s
t
r
e
l
o
r
a
l
c
o
n
t
r
a
c
e
p
t
i
v
e
i
n
h
e
a
l
t
h
y
a
d
u
l
t
s
,
i
n
d
i
c
a
t
i
n
g
t
h
e
d
e
v
e
l
o
p
e
r
s
a
s
s
e
s
s
e
d
C
Y
P
-
m
e
d
i
a
t
e
d
i
n
t
e
r
a
c
t
i
o
n
p
o
t
e
n
t
i
a
l
.
B
e
y
o
n
d
t
h
a
t
,
i
n
t
e
r
a
c
t
i
o
n
r
i
s
k
w
i
t
h
a
n
t
i
d
e
p
r
e
s
s
a
n
t
s
(
t
h
e
i
n
t
e
n
d
e
d
c
o
-
m
e
d
i
c
a
t
i
o
n
)
,
s
t
i
m
u
l
a
n
t
s
,
s
e
i
z
u
r
e
-
t
h
r
e
s
h
o
l
d
-
l
o
w
e
r
i
n
g
a
g
e
n
t
s
,
a
n
d
o
t
h
e
r
g
l
u
t
a
m
a
t
e
r
g
i
c
d
r
u
g
s
i
s
n
o
t
e
s
t
a
b
l
i
s
h
e
d
f
o
r
u
n
s
u
p
e
r
v
i
s
e
d
u
s
e
.
I
t
s
s
t
i
m
u
l
a
n
t
-
l
i
k
e
p
r
o
f
i
l
e
a
n
d
l
o
n
g
h
a
l
f
-
l
i
f
e
r
a
i
s
e
t
h
e
o
r
e
t
i
c
a
l
c
o
n
c
e
r
n
s
f
o
r
c
o
m
b
i
n
i
n
g
w
i
t
h
o
t
h
e
r
a
c
t
i
v
a
t
i
n
g
c
o
m
p
o
u
n
d
s
.
A
n
y
o
n
e
t
a
k
i
n
g
p
r
e
s
c
r
i
p
t
i
o
n
m
e
d
i
c
a
t
i
o
n
s
h
o
u
l
d
t
r
e
a
t
c
o
m
b
i
n
a
t
i
o
n
u
s
e
a
s
u
n
c
h
a
r
a
c
t
e
r
i
z
e
d
a
n
d
c
o
n
s
u
l
t
a
c
l
i
n
i
c
i
a
n
.

Who should avoid it

People with a personal or family history of seizures or epilepsy, given the AMPA-potentiation mechanism
Pregnant or breastfeeding individuals, and adolescents, no safety data
Anyone on prescription antidepressants, stimulants, or seizure-threshold-lowering drugs without clinician oversight
People seeking a proven cognitive enhancer, the human pro-cognitive evidence is not established
Anyone unwilling or unable to independently verify identity and purity of gray-market material

How it is commonly combined

There is no evidence base for stacking TAK-653 with other compounds, and combining an investigational glutamatergic modulator with other actives compounds unknown risk. In its intended clinical context it is studied as an add-on to an existing oral antidepressant, not as part of a nootropic stack. Community stacking with racetams, other AMPA/cholinergic agents, or stimulants is speculative and untested; the long half-life and reported stimulant-like effects make additive activation and sleep disruption plausible concerns. Peptropix does not endorse any stack.

Legal & regulatory. Not FDA-approved for any indication and not a lawful dietary supplement. As osavampator (NBI-1065845/TAK-653) it is an investigational new drug in Phase 3 trials, meaning it lives in a regulated development pipeline, not the consumer market. Material sold to individuals online comes from gray-market vendors labeled "for laboratory research use only, not for human consumption," which places human use outside the lawful and intended channel. It is not a scheduled controlled substance in the US as of this writing, but the research-chemical framing means no FDA review for OTC use and no manufacturing oversight for consumer products. Informational only; Peptropix does not sell it.

Quality & harm reduction

B
e
c
a
u
s
e
t
h
e
r
e
i
s
n
o
l
e
g
i
t
i
m
a
t
e
c
o
n
s
u
m
e
r
s
u
p
p
l
y
c
h
a
i
n
,
a
n
y
T
A
K
-
6
5
3
o
b
t
a
i
n
e
d
b
y
a
n
i
n
d
i
v
i
d
u
a
l
c
o
m
e
s
f
r
o
m
r
e
s
e
a
r
c
h
-
c
h
e
m
i
c
a
l
v
e
n
d
o
r
s
s
e
l
l
i
n
g
p
o
w
d
e
r
o
r
s
o
l
u
t
i
o
n
w
i
t
h
n
o
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
q
u
a
l
i
t
y
a
s
s
u
r
a
n
c
e
.
T
h
e
r
e
i
s
n
o
F
D
A
-
r
e
g
i
s
t
e
r
e
d
m
a
n
u
f
a
c
t
u
r
e
r
,
n
o
U
S
P
m
o
n
o
g
r
a
p
h
,
a
n
d
n
o
i
n
d
e
p
e
n
d
e
n
t
l
o
t
r
e
l
e
a
s
e
f
o
r
c
o
n
s
u
m
e
r
m
a
t
e
r
i
a
l
.
A
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
(
H
P
L
C
i
d
e
n
t
i
t
y
/
p
u
r
i
t
y
,
a
n
d
i
d
e
a
l
l
y
a
n
o
r
t
h
o
g
o
n
a
l
m
e
t
h
o
d
p
l
u
s
h
e
a
v
y
-
m
e
t
a
l
a
n
d
r
e
s
i
d
u
a
l
-
s
o
l
v
e
n
t
s
c
r
e
e
n
i
n
g
)
f
r
o
m
a
n
a
c
c
r
e
d
i
t
e
d
t
h
i
r
d
-
p
a
r
t
y
l
a
b
i
s
t
h
e
m
i
n
i
m
u
m
a
r
e
s
e
a
r
c
h
e
r
w
o
u
l
d
l
o
o
k
f
o
r
,
b
u
t
a
v
e
n
d
o
r
-
s
u
p
p
l
i
e
d
C
O
A
i
s
n
o
t
e
q
u
i
v
a
l
e
n
t
t
o
r
e
g
u
l
a
t
e
d
r
e
l
e
a
s
e
t
e
s
t
i
n
g
a
n
d
c
a
n
b
e
f
a
b
r
i
c
a
t
e
d
.
R
e
c
o
n
s
t
i
t
u
t
i
o
n
a
c
c
u
r
a
c
y
,
s
o
l
v
e
n
t
i
d
e
n
t
i
t
y
,
a
n
d
l
a
b
e
l
-
v
e
r
s
u
s
-
a
c
t
u
a
l
d
o
s
e
a
r
e
a
l
l
u
n
v
e
r
i
f
i
a
b
l
e
w
i
t
h
o
u
t
i
n
d
e
p
e
n
d
e
n
t
a
s
s
a
y
.

Safer, legal alternative we recommend

NMN It To Win It. For the same cellular-aging/longevity goal, our NMN (a NAD+ precursor) is a legal supplement covering a similar mechanism.

See our recommended pick

Find TAK-653 (Osavampator) →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is TAK-653 approved or a legal supplement?

No. It is an investigational drug in clinical trials, not FDA-approved and not a lawful dietary supplement. Consumer sales are gray-market research chemical listings labeled not for human consumption.

Does it actually work for depression?

The Phase 2 SAVITRI trial showed a statistically significant MADRS improvement at the 1 mg dose as an add-on in MDD, which is a genuine but early signal. It is now in Phase 3; efficacy is not yet confirmed by pivotal trials, and it is not proven as a general mood or cognitive enhancer in healthy people.

How is it different from ketamine?

Both are thought to engage AMPA-driven synaptic plasticity, but TAK-653 potentiates AMPA receptors directly and lacks the NMDA blockade responsible for ketamine's dissociative and psychotomimetic effects. Whether that translates to comparable clinical benefit is still being tested.

Is it a nootropic / will it make me smarter?

Cognitive-enhancement claims are largely preclinical and mechanistic. Early human studies showed target engagement and mild stimulant-like effects, but robust human trials demonstrating cognitive enhancement in healthy people do not exist.

What is a safe dose to take?

We do not provide dosing guidance. The only characterized human doses come from supervised trials (1 mg and 3 mg once daily, with 1 mg selected). No self-administration regimen has been validated. Discuss any decision with a qualified clinician.

Is it safe?

In short trials at 1 to 3 mg it was well tolerated with headache and nasopharyngitis as the main adverse events and no serious adverse events reported, but there is no long-term or unsupervised human safety data, the AMPA mechanism carries a theoretical seizure concern, and gray-market purity is unverifiable.

References & further reading

PubMed: TAK-653 AMPA receptor potentiator antidepressant rat
PubMed: TAK-653 healthy volunteers transcranial magnetic stimulation AMPA positive allosteric modulator
PubMed: NBI-1065845 midazolam ethinylestradiol levonorgestrel pharmacokinetics healthy adults
ClinicalTrials.gov: osavampator NBI-1065845 major depressive disorder phase 3
ClinicalTrials.gov: TAK-653 SAVITRI major depressive disorder MADRS